Drug Type Hematopoietic stem cell therapy |
Synonyms- |
Target |
Mechanism CD19 modulators(B-lymphocyte antigen CD19 modulators), CD3 modulators(T cell surface glycoprotein CD3 modulators), Stem cell replacements |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Common Variable Immunodeficiency | Phase 2 | US | 20 Jun 2013 | |
Granulomatous Disease, Chronic | Phase 2 | US | 20 Jun 2013 | |
Hyper-IgM Immunodeficiency Syndrome | Phase 2 | US | 20 Jun 2013 | |
Job Syndrome | Phase 2 | US | 20 Jun 2013 | |
Mendelian susceptibility to mycobacterial disease | Phase 2 | US | 20 Jun 2013 | |
Neutropenia, Severe Chronic | Phase 2 | US | 20 Jun 2013 | |
Wiskott-Aldrich Syndrome | Phase 2 | US | 20 Jun 2013 | |
ZAP70 Deficiency | Phase 2 | US | 20 Jun 2013 |